ProQR will review the recently reported AX-0810 Phase 1 target engagement data and discuss the translational rationale and clinical development strategy for NTCP modulation in biliary atresia, including the framework for evaluating upcoming next-generation AX-0811 Phase 1 data and its potential to treat cholestatic disease.
… in Cambridge, Massachusetts, USA, developing innovative RNA-editing medicines through its proprietary Axiomer™ … strategy, provide medical leadership and advance RNA-editing therapies from concept to clinical evidence. We … shape early clinical-development strategy and help advance RNA-editing therapies for patients. You will combine hands-on …
… event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline … for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the … a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce …
ProQR will host a virtual Investor and Analyst Event highlighting its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”
… call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently … About Axiomer ® ProQR is pioneering a next-generation RNA editing technology called Axiomer ® , which could … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …